Page last updated: 2024-08-17

carbostyril and Dysmyelopoietic Syndromes

carbostyril has been researched along with Dysmyelopoietic Syndromes in 15 studies

Research

Studies (15)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (73.33)	29.6817
2010's	3 (20.00)	24.3611
2020's	1 (6.67)	2.80

Authors

Authors	Studies
Blijlevens, N; de Witte, T; Langemeijer, S; Muus, P; van Bijnen, S	1
Anastasiades, A; Bazdiara, I; Bourikas, G; De Coster, R; De Porre, P; Kotsianidis, I; Margaritis, D; Pantelidou, D; Spanoudakis, E; Tsatalas, C	1
Steensma, DP	1
Epling-Burnette, PK; Loughran, TP	1
Feldman, EJ	2
Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wright, JJ	1
Cortes, JE; Freireich, EJ; Kantarjian, HM; Kurzrock, R; Sebti, SM; Singhania, N; Talpaz, M; Thomas, DA; Wilson, EF; Wright, JJ	1
Cortes, J	2
Albitar, M; Cortes, JE; De Porre, P; Estey, EH; Faderl, SH; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Kurzrock, R; Ryback, ME; Thibault, A; Thomas, DA	1
Adjei, AA; Bruzek, LM; Feldman, EJ; Garrett-Mayer, E; Gojo, I; Gotlib, J; Greenberg, PL; Greer, J; Karp, JE; Kaufmann, SH; Lancet, JE; Liesveld, JL; Morris, L; Park, Y; Wright, JJ	1
Aul, C; Cripe, L; De Porre, P; Fenaux, P; Germing, U; Kantarjian, H; Kerstens, R; Kurzrock, R; Mufti, GJ; Raza, A	1
Cortes, J; Jabbour, E; Kantarjian, H	1
Beran, M; Blascovich, MA; Bucher, C; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; Kurzrock, R; Pilat, SR; Sebti, SM; Verstovsek, S; Wright, JJ	1

Reviews

5 review(s) available for carbostyril and Dysmyelopoietic Syndromes

Article	Year
Novel therapies for myelodysplastic syndromes. Hematology/oncology clinics of North America, 2010, Volume: 24, Issue:2 Topics: Adenine Nucleotides; Aged; Alkylating Agents; Antimetabolites; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; DNA Repair; Drug Therapy, Combination; Drugs, Investigational; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Glutathione; Histone Deacetylase Inhibitors; Humans; Hydrazines; JNK Mitogen-Activated Protein Kinases; Myelodysplastic Syndromes; Quinolones; Sulfonamides; Therapies, Investigational	2010
Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:5 Topics: Age Factors; Animals; Antineoplastic Agents; Drug Delivery Systems; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Quinolones	2010
Farnesyltransferase inhibitors in myelodysplastic syndrome. Current hematologic malignancy reports, 2006, Volume: 1, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Farnesyltranstransferase; Gastrointestinal Diseases; Genes, ras; Hematologic Neoplasms; Humans; Middle Aged; Myelodysplastic Syndromes; Piperidines; Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Treatment Outcome	2006
Farnesyltransferase inhibitors in myelodysplastic syndrome. Current hematology reports, 2005, Volume: 4, Issue:3 Topics: Acute Disease; Aged; Alkyl and Aryl Transferases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Remission Induction; Signal Transduction; Treatment Outcome	2005
Clinical activity of tipifarnib in hematologic malignancies. Expert opinion on investigational drugs, 2007, Volume: 16, Issue:3 Topics: Animals; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Myelodysplastic Syndromes; Quinolones	2007

Trials

8 trial(s) available for carbostyril and Dysmyelopoietic Syndromes

Article	Year
A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia. Leukemia research, 2021, Volume: 105 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Quinolones; Treatment Outcome	2021
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer, 2011, Mar-15, Volume: 117, Issue:6 Topics: Adolescent; Adult; Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Neoplasm Staging; Quinolones; Remission Induction; Risk; Young Adult	2011
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood, 2003, Dec-15, Volume: 102, Issue:13 Topics: Aged; Alkyl and Aryl Transferases; Carrier Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Quinolones; Remission Induction; Signal Transduction; Treatment Outcome; Tumor Necrosis Factor-alpha	2003
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7 Topics: Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antineoplastic Agents; Enzyme Inhibitors; Farnesyltranstransferase; Feasibility Studies; Female; Fibroblast Growth Factor 2; Genes, ras; Humans; Karyotyping; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Myelodysplastic Syndromes; Quinolones; Treatment Outcome; Vascular Endothelial Growth Factor A	2004
Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome. Current hematology reports, 2004, Volume: 3, Issue:3 Topics: Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Blood Cell Count; DNA-Binding Proteins; Dose-Response Relationship, Drug; Farnesyltranstransferase; Humans; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; STAT3 Transcription Factor; Trans-Activators; Treatment Outcome	2004
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood, 2007, Feb-15, Volume: 109, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Farnesyltranstransferase; Female; HSP40 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Quinolones; Remission Induction; Risk; Survival Rate; Treatment Outcome	2007
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood, 2007, May-15, Volume: 109, Issue:10 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Quinolones; Risk; Survival Analysis; Treatment Outcome	2007
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jan-15, Volume: 14, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Drug Administration Schedule; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Quinolones	2008

Other Studies

2 other study(ies) available for carbostyril and Dysmyelopoietic Syndromes

Article	Year
In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors. Acta haematologica, 2008, Volume: 120, Issue:1 Topics: Aged; Apoptosis; Colony-Forming Units Assay; Enzyme Inhibitors; Farnesyltranstransferase; Female; Hematopoiesis; Humans; Immunomagnetic Separation; In Vitro Techniques; Male; Middle Aged; Myelodysplastic Syndromes; Myeloid Progenitor Cells; Neoplastic Stem Cells; Quinolones	2008
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clinical lymphoma, 2003, Volume: 4 Suppl 1 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperidines; Pyridines; Quinolones	2003

Article

Year

In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors.

Acta haematologica, 2008, Volume: 120, Issue:1

Topics: Aged; Apoptosis; Colony-Forming Units Assay; Enzyme Inhibitors; Farnesyltranstransferase; Female; Hematopoiesis; Humans; Immunomagnetic Separation; In Vitro Techniques; Male; Middle Aged; Myelodysplastic Syndromes; Myeloid Progenitor Cells; Neoplastic Stem Cells; Quinolones

2008

Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.

Clinical lymphoma, 2003, Volume: 4 Suppl 1

Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperidines; Pyridines; Quinolones

2003